<DOC>
	<DOCNO>NCT01896401</DOCNO>
	<brief_summary>The InSeal vascular closure device ( VCD ) assess percutaneous closure artery access sit quick hemostasis ambulation patient undergone large bore endovascular catheterization procedure . The study hypothesis VCD safe efficaient achieve hemostasis study population .</brief_summary>
	<brief_title>InSeal Vascular Closure Device Clinical Study Protocol</brief_title>
	<detailed_description />
	<criteria>Candidate large bore catheterization procedure ( TAVI , aortic endograft repair ) use CE approve 18Fr access sheath . Subject age least 18 year Patient sign recent approved version Informed Consent Existence additional arterial access port require instance occlude balloon plan use safety precaution . Women Of Child Bearing Potential ( WOCBP ) Legally noncompetent patient Patient participate another clinical study time InSeal VCD study Prior target artery closure vascular closure device intravascular component ( AngioSeal ) 30 day prior catheterization Subjects know coagulopathy , preexist hematoma , arteriovenous fistula , pseudoaneurysm vessel access site prior artery closure Patients tolerate aspirin clopidogrel anticoagulation treatment Prior vascular surgery vascular graft region access site Significant calcification , atherosclerotic disease , stent within 1.5 cm puncture site may interfere operation experimental device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>large bore endovascular catheterization procedure</keyword>
	<keyword>Vascular Closure Device</keyword>
</DOC>